ROBERT J. SPIEGEL, M.D., FACP - Corporate Board Profile

GERON CORP

Filing Date	Source Excerpt
2011-03-28	Robert J. Spiegel, M.D., FACP, has served as a director of the Company since May 2010. The Audit Committee, which is comprised of Ms. Eastham and Messrs. Fritzky and Kiley. The following table provides compensation information for the year ended December 31, 2010 for each non-employee member of the Board. Spiegel, Robert $ 4,500 53,640 129,335 187,475
2012-04-03	Robert J. Spiegel, M.D., FACP, has served as a director of the Company since May 2010... The Compensation Committee, which is comprised of Drs. Hofstaetter, Lawlis (who joined in March 2012) and Spiegel, met seven times in 2011... Director Compensation Table shows total compensation of $126,350.
2013-04-05	Robert J. Spiegel, M.D., FACP, has served as a director of Geron since May 2010. ... The Board believes Dr. Spiegel's extensive medical experience developing oncology products ... qualifies Dr. Spiegel to serve as a director. ... The Compensation Committee, which is comprised of Drs. Hofstaetter, Lawlis (who joined in March 2012) and Spiegel, met 12 times in 2012. ... The following table provides compensation information for the fiscal year ended December 31, 2012 for each non-employee member of the Board. ... Spiegel, Robert $63,917 in fees and $28,424 in option awards totaling $92,341.
2014-04-04	Robert J. Spiegel, M.D., FACP, has served as a director of Geron since May 2010. Dr. Spiegel currently serves as Chief Medical Officer of PTC Therapeutics, Inc. He is also a director of Edge Therapeutics, Inc., a biopharmaceutical company focused on products for acute, fatal or debilitating conditions, and Avior Computing Corporation, a governance risk and compliance process technology company. He also is an Associate Fellow at the University of Pennsylvania Center for Bioethics and an Associate Professor at the Weill Cornell Medical School. He served as a director for the Cancer Institute of New Jersey from 1999 to 2009 and as a director of Cancer Care New Jersey from 1995 to 2011. After 26 years with the Schering-Plough Corporation (now Merck & Co.), a global healthcare company, Dr. Spiegel retired in 2009 as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. He initially joined Schering-Plough as Director of clinical research for oncology and rose to hold various positions including Vice President of clinical research and Senior Vice President of worldwide clinical research. As Senior Vice President of worldwide clinical research, Dr. Spiegel managed Phase 1 to Phase 3 clinical development in all therapy areas, including allergy, respiratory, cardiovascular, immunology, dermatology, oncology and infectious diseases. As Chief Medical Officer, Dr. Spiegel was involved with over 30 New Drug Applications, participated in multiple due diligence reviews and in-licensing decisions, re-engineered pharmacovigilence and risk management areas and built a quality system for all research operations. Following a residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania. The Compensation Committee, which is comprised of Drs. Hofstaetter, Lawlis and Spiegel, met seven times in 2013. Each of the members of the Compensation Committee is "independent," as required by NASDAQ Rules 5605(a)(2) and 5605(d)(2). In determining whether Drs. Hofstaetter, Lawlis and Spiegel are independent within the meaning of NASDAQ Rules pertaining to membership of the Compensation Committee that will be in effect for us as of the Annual Meeting, our Board determined, based on its consideration of factors specifically relevant to determining whether any such director has a relationship to us that is material to that director's ability to be independent from management in connection with the duties of a compensation committee member, that no member of the Compensation Committee has a relationship that would impair that member's ability to make independent judgments about our executive compensation. The Compensation Committee's responsibilities include making recommendations concerning compensation of executive officers, administering Geron's incentive compensation and benefit plans, and performing such other functions regarding compensation as the Board may delegate. The following table provides compensation information for the fiscal year ended December 31, 2013, or fiscal 2013, for each non-employee member of the Board who served in such capacity during fiscal 2013. Dr. Scarlett does not receive any compensation for his Board service. The following table sets forth the following information with respect to non-employee directors (nine persons) for the fiscal year ended December 31, 2013: (i) stock options granted under the 2006 Directors' Plan; and (ii) the grant date fair value of stock options granted.
2015-04-03	Robert J. Spiegel, M.D., FACP, has served as a director of Geron since May 2010. He is a member of the Compensation Committee. Compensation Table shows total compensation of $106,452.
2016-04-01	Robert J. Spiegel, M.D., FACP, has served as a director of Geron since May 2010. ... The Compensation Committee, which met eight times in 2015, was comprised of Drs. Hofstaetter, Lawlis and Spiegel, until Dr. Hofstaetter's retirement from the Board and the Compensation Committee on the date of our Annual Meeting in May 2015. The Board appointed Ms. Eastham to the Compensation Committee as of the date of our Annual Meeting in May 2015, thereafter our Compensation Committee has been comprised of Drs. Lawlis and Spiegel and Ms. Eastham. ... The following table provides compensation information for the fiscal year ended December 31, 2015 ("fiscal 2015"), for each non-employee member of the Board who served in such capacity during fiscal 2015. ... Spiegel, Robert $ 57,500 $ 96,229 $ 153,729
2017-03-24	Robert J. Spiegel, M.D., FACP 67 Yes C 2 Independent Director ... Geron Committee Memberships - Compensation Committee (Chair) ... Director Compensation Table ... Spiegel, Robert $57,500 $97,760 $155,260
2018-03-30	Robert J. Spiegel, M.D., FACP 68 Yes C 2 Independent Director
2019-04-22	Robert J. Spiegel, M.D., FACP 69 Yes C 2 Independent Director Dr. Spiegel has served as a director of Geron since May 2010. Dr. Spiegel currently serves as an Associate Professor at the Weill Cornell Medical School, a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund.
2020-04-14	Dr. Spiegel has served as a director of Geron since May 2010. Dr. Spiegel currently serves as an Associate Professor at the Weill Cornell Medical School, a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund. He is also a member of the board of directors of Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases, since September 2018; and several privately-held biotechnology companies. He previously served as a director for Avior Computing Corporation, a privately-held governance risk and compliance process technology company, from October 2011 to November 2017; Talon Therapeutics, Inc., a biopharmaceutical company, from July 2010 to July 2013; Capstone Therapeutics Corp., a biotechnology company, from May 2010 to January 2012; Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, from January 2015 to January 2018; and PDS Biotechnology Corporation (formerly Edge Therapeutics, Inc.), a biotechnology company, from August 2013 to March 2019; the Cancer Institute of New Jersey from 1999 to 2009; and Cancer Care New Jersey from 1995 to 2011. From March 2011 to April 2016, Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing treatments for rare disorders. In 2009, after 26 years with the Schering-Plough Corporation (now Merck & Co.), a global healthcare company, Dr. Spiegel retired as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. His career at Schering-Plough involved various positions, including Director of clinical research for oncology, Vice President of clinical research, and Senior Vice President of worldwide clinical research. Following a residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. The Board believes Dr. Spiegel’s extensive medical experience developing oncology products, his deep understanding of pharmaceutical research and development, and broad expertise in gaining regulatory approval for drug candidates, enhances the Board’s ability to critically assess the progress and potential of imetelstat, and qualifies Dr. Spiegel to serve as a director. Drs. Lawlis and Spiegel and Ms. Eastham served on the Compensation Committee for the year ended December 31, 2019.
2021-03-22	Robert J. Spiegel, M.D., FACP 71 Yes C 3 Independent Director
2022-03-22	Robert J. Spiegel, M.D., FACP 72 Yes C 3 Independent Director Spiegel, Robert 57,504 74,750 132,254
2023-04-12	Robert J. Spiegel, M.D., FACP 73 Yes AC: C Compensation: $182,698
2024-03-27	Robert J. Spiegel, M.D., FACP has served as a director of Geron since May 2010. The Board believes Dr. Spiegel’s extensive medical experience developing oncology products, his deep understanding of pharmaceutical research and development, and broad expertise in gaining regulatory approval for drug candidates, enhances the Board’s ability to critically assess the progress and potential of imetelstat, and qualifies Dr. Spiegel to BE ELECTED as a director. For the year ended December 31, 2023, Dr. Spiegel received $57,498 in cash fees and $293,400 in stock option awards, totaling $350,898.
2025-04-08	Robert J. Spiegel, M.D., FACP, has served as a director of Geron since May 2010. ... The current members of the Compensation Committee are Dr. Aggarwal, Dr. Spiegel, and Dr. Molineaux. ... The current members of the Nominating and Corporate Governance Committee are Drs. Lawlis, Molineaux, and Spiegel.